Study Summary
This trial will study how well erenumab works to improve satisfaction with migraine medication.
Eligible Conditions
- Migraine
Treatment Effectiveness
Effectiveness Progress
This is further along than 93% of similar trials
Study Objectives
1 Primary · 8 Secondary · Reporting Duration: Week 24
Baseline and Week 24
Mean Change from Baseline in Emotional Function Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in Physical Function Domain Score as Measured by the Migraine Functional Impact Questionnaire (MFIQ) at Week 24
Mean Change from Baseline in Social Function Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in Usual Activities Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) Overall Satisfaction Scale Score at Week 24
Week 24
Number of Clinician's Reporting Improvement in Treating Clinician's Global Impression at Week 24
Number of Key Family Member's Reporting Improvement in Key Family Member's Impression at Week 24
Number of Participants Achieving Overall Satisfaction at Week 24
Number of Participants Reporting Improvement in Participant Global Impression at Week 24
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Side Effects for
140 mg Erenumab SC
16%Constipation
6%Covid-19
Trial Design
1 Treatment Group
Erenumab
1 of 1
Experimental Treatment
322 Total Participants · 1 Treatment Group
Primary Treatment: Erenumab · No Placebo Group · Phase 4
Erenumab
Drug
Experimental Group · 1 Intervention: Erenumab · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erenumab
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 24
Who is running the clinical trial?
AmgenLead Sponsor
1,296 Previous Clinical Trials
1,328,496 Total Patients Enrolled
17 Trials studying Migraine
6,410 Patients Enrolled for Migraine
MDStudy DirectorAmgen
838 Previous Clinical Trials
897,597 Total Patients Enrolled
17 Trials studying Migraine
6,410 Patients Enrolled for Migraine
Eligibility Criteria
Age 18 - 99 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have had migraine for at least 12 months.
You have a history of migraine with or without aura for at least 3 months on average across the 3 months prior to screening.
You report to your provider intolerance or insufficient response with your current preventative treatment.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments